RxDoctor Payments Data

Pamela Homer, APRN

Psychiatric/Mental Health · Rockledge, FLNPI 1124162995

Payments from drug & device makers

$3,677in general payments, 2019–2025

Across 173 payments — averaging $21.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$831
  • Alkermes, Inc.$579
  • Neurocrine Biosciences, Inc.$497
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$464
  • Johnson & Johnson$350
  • Otsuka America Pharmaceutical, Inc.$306
  • plus $652 from 7 others

What the payments were for

  • Food & beverage$3,677100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,677 in reported general payments places this provider in the 85th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$23,041
Medicare patients
24
Services billed
266

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrintellixVortioxetine Hydrobromide11$6,049
Aripiprazole17$3,319
Desvenlafaxine Succinate ErDesvenlafaxine Succinate11$1,555
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine16$768
Lamotrigine67$665
Quetiapine Fumarate43$575
Hydroxyzine Hcl26$549
Duloxetine Hcl35$466
Bupropion XlBupropion Hcl14$371
Benztropine Mesylate17$322
Gabapentin20$244
Mirtazapine27$239
Olanzapine28$226
Buspirone Hcl13$225
Escitalopram Oxalate39$221

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$91$6,04911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Rockledge

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →